- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Victoria Bae-Jump on Challenges in Treating Patients With Endometrial Cancer
I think the hardest thing about advanced and recurrent endometrial cancer is that the outcomes are still fairly poor, explained Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center.
I think the hardest thing about advanced and recurrent endometrial cancer is that the outcomes are still fairly poor, explained Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center.
Transcript
What challenges are you faced with in the treatment of patients with advanced and/or recurrent endometrial cancer?
I think the hardest thing about advanced and recurrent endometrial cancer is that the outcomes are still fairly poor for advanced endometrial cancers. You know, the overall 5-year survival is anywhere from 15% to 40%, depending on hat study you have, and we don’t have a very long list of agents, cytotoxics or targeted agents, that endometrial cancer responds to. Recurrent disease is even more dismal for endometrial cancer with actually survival after the diagnosis of recurrence being only between 14 and 15 months.
So, I think the hardest thing is that we don’t have many good treatments to offer advanced and recurrent endometrial cancer patients once we get passed paclitaxel and carboplatin. So, I think that’s the hardest thing to tell patients, that we don’t have as many options as we would like for them to be treated with.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
